Cargando…

Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?

Clostridioides difficile infection (CDI) is a pressing health care issue due to the limited effectiveness of current treatments and high recurrence rates. Current available antibiotic options for CDI disrupt the fecal microbiome which predisposes recurrent CDI. Fecal microbiota transplantation (FMT)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagarakanti, Sandhya, Orenstein, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208241/ https://www.ncbi.nlm.nih.gov/pubmed/37235073 http://dx.doi.org/10.2147/IDR.S400570

Ejemplares similares

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
por: Orenstein, Robert, et al.
Publicado: (2023)

The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota
por: Zhang, Yongrong, et al.
Publicado: (2022)

Clostridioides difficile infection: microbe-microbe interactions and live biotherapeutics
por: Wang, Ruojun
Publicado: (2023)

Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2023)

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities
por: Tillotson, Glenn, et al.
Publicado: (2022)

Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection
por: Papazyan, Romeo, et al.
Publicado: (2023)

Clostridioides difficile therapeutics: guidelines and beyond
por: Orenstein, Robert, et al.
Publicado: (2019)

Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo
por: Murphy, Christopher K, et al.
Publicado: (2023)

1042. Safety of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
por: Braun, Tricia, et al.
Publicado: (2021)

129. Antimicrobial Resistance Genes Were Reduced Following Administration of Investigational Microbiota-Based Live Biotherapeutic RBX2660 to Individuals with Recurrent Clostridioides difficile Infection
por: Hau, Heidi, et al.
Publicado: (2021)

167. Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
por: Bancke, Lindy, et al.
Publicado: (2021)

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
por: Lee, Christine, et al.
Publicado: (2023)

The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660
por: Orenstein, Robert
Publicado: (2022)

Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

1064. Treatment Success in Reducing Recurrent Clostridioides difficile Infection with Investigational Live Biotherapeutic RBX2660 Is Associated with Microbiota Restoration: Consistent Evidence from a Phase 3 Clinical Trial
por: Blount, Ken, et al.
Publicado: (2021)

Microbiome engineering: engineered live biotherapeutic products for treating human disease
por: Rutter, Jack W., et al.
Publicado: (2022)

Fecal Microbiota Transplantation Is Effective for the Treatment of Partially Treated Clostridioides difficile Infection
por: Cho, Young-Seok
Publicado: (2021)

Ischemic colitis complicated by Clostridioides difficile infection treated with fecal microbiota transplantation
por: Kang, Seok Hyung, et al.
Publicado: (2023)

Editorial: Synthetic Live Biotherapeutic Products for Diseases
por: Chen, Ye, et al.
Publicado: (2022)

Fecal Microbiota of Toxigenic Clostridioides difficile-Associated Diarrhea
por: Hernández, Marta, et al.
Publicado: (2019)

Fecal microbiota transplantation beyond Clostridioides difficile infections
por: Wortelboer, Koen, et al.
Publicado: (2019)

Intestinal Microbiota in Elderly Inpatients with Clostridioides difficile Infection
por: Vakili, Bahareh, et al.
Publicado: (2020)

Fecal Microbiota Transplantation beyond Clostridioides Difficile Infection
por: Moon, Chang Mo, et al.
Publicado: (2021)

54101 Characterizing Microbiota Features of Clostridioides difficile Infections
por: Tomkovich, Sarah, et al.
Publicado: (2021)

Microbial ecology between Clostridioides difficile and gut microbiota
por: KAMIYA, Shigeru
Publicado: (2023)

Microbiota-based markers predictive of development of Clostridioides difficile infection
por: Berkell, Matilda, et al.
Publicado: (2021)

Gut microbiota features associated with Clostridioides difficile colonization in puppies
por: Berry, Alexander S. F., et al.
Publicado: (2019)

Uncovering the Harms of Treating Clostridioides difficile Colonization
por: Polage, Christopher R., et al.
Publicado: (2021)

Factors that influence clinical efficacy of live biotherapeutic products
por: Pot, Bruno, et al.
Publicado: (2021)

RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients’ Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections
por: Khanna, Sahil, et al.
Publicado: (2020)

Recent advances in the treatment of C. difficile using biotherapeutic agents
por: Giau, Vo Van, et al.
Publicado: (2019)

Insights into the Role of Human Gut Microbiota in Clostridioides difficile Infection
por: Kachrimanidou, Melina, et al.
Publicado: (2020)

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
por: Sandhu, Avnish, et al.
Publicado: (2021)

Gut Microbiota Composition Associated with Clostridioides difficile Colonization and Infection
por: Martinez, Elisa, et al.
Publicado: (2022)

Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients
por: Ali, Hiba, et al.
Publicado: (2021)

Pathogenicity and virulence of Clostridioides difficile
por: Buddle, Jessica E., et al.
Publicado: (2023)

Immunotherapy could be answer to treating novel coronavirus
Publicado: (2013)

Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample
por: Novakova, Elena, et al.
Publicado: (2021)

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
por: Dubberke, Erik R., et al.
Publicado: (2022)

Live Biotherapeutic Products, A Road Map for Safety Assessment
por: Rouanet, Alice, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ou0du8k4e8d1veqfkh1gvhmh68